Zilovertamab
Publications
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies (Rule et al, Br J Haem 2017)
Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell
lymphoma (Yu et al., Oncotarget 2018)
Phase 1 Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia (Choi et al, Cell Stem Cell, 2018)
Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody (Zhang et al.,
PNAS 2019)
Ovarian Cancer Stem Cells Express ROR1, Which Can Be Targeted
for Anti-Cancer-Stem-Cell
Therapy (Zhang et al., PNAS 2014)
Conference Presentations
Study ZILO-301 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab Plus Ibrutinib vs. Ibrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (EHA 2022, S. Yazji)
Phase 1/2 Study of Zilovertamab (formerly Cirmtuzumab) and Ibrutinib in Mantel Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) (Lee et al., ASCO 2022 Annual Meeting)
Lee 2021 ASH Poster Zilovertamab + Ibrutinib for MCL
Lee 2021 ASH Presentation Zilovertamab + Ibrutinib for MCL
Phase 1/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)
Phase 1/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) - VIDEO
A Phase 1b Trial of Cirmtuzumab and Paclitaxel in Locally Advanced/Unresectable or Metastatic Her2 Negative Breast Cancer (Shatsky et al., AACR 2021 Virtual Annual Meeting)
Inhibition of Ovarian and Endometrial Cancer Cell Proliferation by an Anti-ROR1 Monoclonal Antibody (Liu et al., AACR 2021 Virtual Annual Meeting)
Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study (Lee et al., ASH 2020 Virtual Annual Meeting)
Clinical Activity of Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib; Interim Results of a Phase 1b/2 Study in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) (Lee et al., ASCO 2020 Virtual Annual Meeting)
Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe
and Effective: Planned Analysis of the CIRLL Phase 1/2 Trial for CLL and MCL (Choi et al,. ASH Annual
Meeting 2019)
A Phase 1b Trial of Cirmtuzumab and Paclitaxel in Locally Advanced /Unresectable or Metastatic Her2
Negative Breast Cancer (Shatsky et al., San Antonio Breast Cancer Symposium 2019)
ONCT-808
Publications
The
Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers (Zhang et al. , Am
J Pathol 2012)
Conference Presentations
S. Meinke 2022 EHA Poster Preclinical Evaluation of Zilovertamab-Based Anti-ROR1 Chimeric Antigen Receptors in NK and T Cells
Preclinical Evaluation of Anti-ROR1 CAR T-cells Employing a ROR1 Binding scFv Derived
From the Clinical Stage mAb Cirmtuzumab (Prussak et al.,
2020 ASCO-SITC Clinical Immuno-Oncology Symposium)
ONCT-534
Publications
Antonarakis 2012 NEJM - AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Conference Presentations
AACR-NCI-EORTC Molecular Targets and Cancer Therapuetics Conference Presentation_October 2021
ONCT-216
Publications
Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced
vincristine sensitivity in Ewing’s sarcoma (Zöllner et al., Science Signaling 2017)
YK-4-279
Effectively Antagonizes EWS-FLI1 Induced Leukemia in a Transgenic Mouse Model (Minas
et al., Oncotarget 2015)
A Small Molecule
Inhibitor of ETV1, YK-4-279, Prevents Prostate Cancer Growth and Metastasis
in a Mouse Xenograft Model (Rahim et al., PLoS One 2014)
A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of
Ewing’s sarcoma (Erzikan et al., Nature Medicine 2009)
Conference Presentations
TK216 for Relapsed/Refractory Ewing Sarcoma - Interim Phase 1/2 Results
TK216 for Relapsed/Refractory Ewing Sarcoma - Interim Phase 1/2 Results - VIDEO
TK216 Phase 1 Study in Metastatic, Relapsed/Refractory Ewing Sarcoma (Ludwig, CTOS 2020)
A Phase 1, Dose Escalation Study of Intravenous
TK216 in Patients with Relapsed or Refractory
Ewing Sarcoma (Meyers, CTOS 2019)
The ETS inhibitors YK-4-279 and TK216 interfere with SPIB and synergize with lenalidomide in diffuse
large B cell lymphoma of the activated B cell-like type (ABC DLBCL) (Chung et al., ASH Annual Meeting
2017)